Luminex Builds Genetic Test Portfolio Via Tm Bioscience Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Luminex's purchase of DNA-based test maker Tm Bioscience gives the firm full ownership of comprehensive molecular diagnostic kits previously produced collaboratively by the companies
You may also be interested in...
People In Brief
Siemens Healthcare: Michael Reitermann is the CEO of Siemens' U.S. health care business as of July 1. Since 2002, he has been running the firm's molecular imaging unit. Before that, he was a VP of Siemens' global angiography, fluoroscopy and X-ray business. Heinrich Kolem, who Reitermann is replacing, has been named global head of the angiography, fluoroscopy and X-ray division
People In Brief
Siemens Healthcare: Michael Reitermann is the CEO of Siemens' U.S. health care business as of July 1. Since 2002, he has been running the firm's molecular imaging unit. Before that, he was a VP of Siemens' global angiography, fluoroscopy and X-ray business. Heinrich Kolem, who Reitermann is replacing, has been named global head of the angiography, fluoroscopy and X-ray division
Luminex Launches 12-Test Viral Panel In Time For Flu Season
Luminex launched its xTAG Respiratory Viral Panel Jan. 3, with plans for a quick ramp-up to capture market in the current flu season